Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

2articles mentioning institutions

2institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: NCT05274815 ×

NCT05274815

This institution is selected. Its supporting articles are shown below.

NCT052748152

Articles mentioning NCT05274815

2 articles · page 1 of 1

P198 Tezepelumab reduces OCS use and improves sino-nasal symptoms in OCS-dependent patients with severe asthma and comorbid chronic rhinosinusitis (overall and with nasal polyps): results from the phase 3b WAYFINDER study

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

89.9%

WAYFINDER NCT05274815 tezepelumab Chronic rhinosinusitis prednisone CRSwNP CRS severe asthma

…s 28 and 52.Results Of 298 patients who received tezepelumab in WAYFINDER, 74 (24.8%) had CRS and 36 (12.1%) had CRSwNP. By week 52, 87.8…

P202 On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

78.7%

NCT03347279 NCT05274815 tezepelumab severe asthma severe uncontrolled asthma

… In the phase 3 NAVIGATOR study in severe uncontrolled asthma ( NCT03347279), 28.5% of tezepelumab recipients achieved on-treatment clinica…